Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Authors

Sophie Leboulleux

Published

June 27, 2024

Abstract

Nintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC).

Supporters

Support the authors with ResearchCoin

Journal

Frontiers in Endocrinology

Topics

Medicine

Cancer Oncology

Internal Medicine

Endocrinology, Diabetes And Metabolism

Pulmonary And Respiratory Medicine

DOI

10.3389/fendo.2024.1403687

License

CC-BY

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Authors

Sophie Leboulleux

Published

June 27, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Frontiers in Endocrinology

Topics

Medicine

Cancer Oncology

Internal Medicine

Endocrinology, Diabetes And Metabolism

Pulmonary And Respiratory Medicine

DOI

10.3389/fendo.2024.1403687

License

CC-BY

Paper

Paper

Paper

Paper

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Abstract

Supporters

Journal

Topics

DOI

License

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

Abstract

Supporters

Journal

Topics

DOI

License

Supporters

Journal

Topics

DOI

License